The Problem of Rarity: Estimation of Prevalence in Rare Disease

被引:46
作者
Auvin, Stephane [1 ]
Irwin, John [2 ]
Abi-Aad, Paul [3 ]
Battersby, Alysia [3 ]
机构
[1] Univ Paris Diderot, Serv Neurol Pediat, Paris, France
[2] Zogenix Int Ltd, Maidenhead, Berks, England
[3] Wickenstones, Abingdon, Oxon, England
关键词
Dravet syndrome; epidemiology; incidence; prevalence; rare disease; SEVERE MYOCLONIC EPILEPSY; DE-NOVO MUTATIONS; DRAVET-SYNDROME; SCN1A MUTATIONS; INFANCY; MORTALITY; ENCEPHALOPATHY; EPIDEMIOLOGY; STIRIPENTOL; TRUNCATION;
D O I
10.1016/j.jval.2018.03.002
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: From a disease's first description to its wider recognition, factors such as changes over time in diagnostic criteria, available therapies, and subsequent mortality rates may influence diagnosed prevalence of rare diseases. Objectives: To propose a novel methodology for estimating the true prevalence of rare diseases using current incidence adjusted to changing diagnostic practice over time. This article focuses on rare diseases whose diagnosis may have changed over time, and raises the hypothesis that prevalence calculated from current incidence may be higher than diagnosed prevalence, which may lag behind the current disease definition and diagnostic methods. A rare epileptic encephalopathy, Dravet syndrome (DS), is explored as an illustrative example. Methods: A targeted literature review was performed for DS to identify all reported incidence, prevalence, and mortality and depict how diagnostic practice has evolved over time. A conceptual model was developed to calculate prevalence derived from current incidence figures alone (incidence-derived prevalence) or incidence adjusted with factors that cause a diagnostic drag (diagnostic awareness-adjusted prevalence). Results: We identified sufficient publications of incidence and prevalence to test the conceptual model. For pediatric patients with DS, diagnosed prevalence in the field (as reported in current literature) matches incidence-derived prevalence, whereas for adult patients, it is overestimated by incidence-derived prevalence, but not by diagnostic awareness-adjusted prevalence. Conclusions: Care should be taken with current incidence-derived prevalence figures to not overstate the prevalence in rare diseases, as methodological challenges in counting small populations, coupled with advances in rare disease discovery, may cause discrepancies.
引用
收藏
页码:501 / 507
页数:7
相关论文
共 49 条
  • [1] Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid
    Alpsoy, Erkan
    Akman-Karakas, Ayse
    Uzun, Soner
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2015, 307 (04) : 291 - 298
  • [2] PROPOSAL FOR REVISED CLASSIFICATION OF EPILEPSIES AND EPILEPTIC SYNDROMES
    不详
    [J]. EPILEPSIA, 1989, 30 (04) : 389 - 399
  • [3] [Anonymous], 2016, WORLD FACTBOOK
  • [4] The incidence of SCN1A-related Dravet syndrome in Denmark is 1: 22,000: A population-based study from 2004 to 2009
    Bayat, Allan
    Hjalgrim, Helle
    Moller, Rikke S.
    [J]. EPILEPSIA, 2015, 56 (04) : E36 - E39
  • [5] Rare-disease genetics in the era of next-generation sequencing: discovery to translation
    Boycott, Kym M.
    Vanstone, Megan R.
    Bulman, Dennis E.
    MacKenzie, Alex E.
    [J]. NATURE REVIEWS GENETICS, 2013, 14 (10) : 681 - 691
  • [6] Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
    Brunklaus, A.
    Ellis, R.
    Reavey, E.
    Forbes, G. H.
    Zuberi, S. M.
    [J]. BRAIN, 2012, 135 : 2329 - 2336
  • [7] Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology
    Catarino, Claudia B.
    Liu, Joan Y. W.
    Liagkouras, Ioannis
    Gibbons, Vaneesha S.
    Labrum, Robyn W.
    Ellis, Rachael
    Woodward, Cathy
    Davis, Mary B.
    Smith, Shelagh J.
    Cross, J. Helen
    Appleton, Richard E.
    Yendle, Simone C.
    McMahon, Jacinta M.
    Bellows, Susannah T.
    Jacques, Thomas S.
    Zuberi, Sameer M.
    Koepp, Matthias J.
    Martinian, Lillian
    Scheffer, Ingrid E.
    Thom, Maria
    Sisodiya, Sanjay M.
    [J]. BRAIN, 2011, 134 : 2982 - 3010
  • [8] Ceulemans B, 2004, ACTA NEUROL BELG, V104, P95
  • [9] Chial H., 2008, NATURE ED, V1, P192
  • [10] Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial
    Chiron, C
    Marchand, MC
    Tran, A
    Rey, E
    d'Athis, P
    Vincent, J
    Dulac, O
    Pons, G
    [J]. LANCET, 2000, 356 (9242) : 1638 - 1642